Cardiac safety in cluster headache patients using the very high dose of verapamil (≥720 mg/day)

Table 1 Cardiac safety of the very high verapamil CH patients

	Sex	Age	TU	CVH	CH	vD	vSMD	SM	ACT	PCT	EKG changes	SAE	vC	CAE
1	M	50	Present	No	C	108	96	1,200	scS	No	No			No
2	M	21	No	No	E	84	72	960	scS	No	Second degree HB	Yes	Stop	No
3	M	45	Present	No	E	12	2	960	scS	No	Bradycardia	No	No	No
4	M	47	Present	No	C	72	60	840	scS	T	Bradycardia	No	No	No
5	M	55	Past	HBP	E	1	1	720	scS	No	No			D
6	M	34	Present	No	C	12	1	720	scS	No	No			No
7	M	50	Present	No	C	36	24	1,440	scC	No	Bradycardia	No	No	L
8	M	33	Present	No	E	48	1	720	scC	No	No			No
9	M	46	Past	No	E	1	1	720	scC	No	No			L
10	M	37	Present	No	E	1	1	720	scC	No	No			C
11	M	72	Present	No	E	3	2.5	960	O₂	No	No			C
12	M	51	Past	No	C	36	24	1,440	oZ	No	Third degree HB	Yes	Stop	L–D
13	M	49	Present	No	C	120	96	960	scC	L	No			No
14	M	52	Present	No	E	1	1	840	scC	No	First HB	Yes	↓600	D–E
15	M	30	No	No	E	1	1	960	No	No	Bradycardia	No	No	No
16	M	33	Present	No	C	25	24	720	scS	T-I	Bradycardia	No	No	L
17	M	37	Present	HBP	C	72	71	720	scC	G	First HB	Yes	↓840	No
18	M	40	Present	No	C	47	46	960	scC	No	No			L–E
19	M	53	Past	HBP	C	96	93	720	scC	No	No			L–D–I
20	M	37	Present	No	C	76	53	720	scC-O₂	No	No			L–D–E
21	M	42	Present	No	C	17	10	720	scC	I	No			L–E–G
22	W	34	Past	No	C	18	10	720	scC-O₂	No	No			L
23	M	55	Present	No	C	53	51	720	scC	No	No			L
24	M	41	Present	No	C	84	58	960	scC	No	No			L–D–E
25	M	28	Present	No	C	37	36	720	scC-O ₂	No	Bradycardia	No	No	L
26	M	31	Present	No	C	81	46	720	scC	I	No			No
27	M	52	Present	No	C	27	24	1,440	scC	I	Bradycardia	No	↓1,200	No
28	H	54	Past	CAD	C	71	53	720	scC	No	No			No
29	H	33	Present	No	C	96	85	720	scC	No	No			L

Sex, age (years), tobacco use (TU), cardiovascular history (CVH) with high blood pressure (HBP) and coronary arteries disease (CAD), type of CH (E: episodic CH–C: chronic CH), duration of verapamil use (vD) in months, duration of supra-maximum dose of verapamil (vSMD) in months, supra-maximum dose of verapamil achieved (SM) in mg/day, acute concomitant treatments (ACT/scC: subcutaneous sumatriptan–oZ: oral –O₂: oxygen), prophylactic concomitant treatments (PCT/I: indomethacin–G: gabapentin–L: lithium–T: topiramate), electrocardiogram (EKG) changes, serious adverse event (SAE), change in verapamil dose (vC), clinical adverse events (CAE/C: constipation–D: dyspnea–E: edema of lower limbs–G: gingival hyperplasia–I: impotence–L: lethargy)
Patients with serious cardiac adverse event are in bold and patient with nonserious cardiac adverse event are in italics

ISSN: 1129-2377